Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 1, Pages 6-13Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2011.516
Keywords
HER2; breast cancer; afatinib; trastuzumab; T-DM1; lapatinib
Categories
Funding
- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)
- Terry Fox Foundation Canada [020017]
Ask authors/readers for more resources
The use of trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) alteration present in 25 to 30% of breast cancers, has been associated with improved survival outcomes in both the adjuvant and metastatic settings. However, despite the robust clinical efficacy of trastuzumab in HER2-positive metastatic breast cancer (MBC), primary and secondary resistance remains a clinical challenge. Although lapatinib has demonstrated modest activity in this setting, trials reported to date have yet to demonstrate improvements in overall survival with its use. Novel therapeutic strategies to circumvent trastuzumab resistance are warranted, and agents targeting the HER, vascular endothelial growth factor, heat shock protein 90, phosphoinositide 3 kinase/Akt/mammalian target of rapamycin, and insulin-like growth factor-1 receptor pathways represent rational approaches in the management of HER2-positive disease. In this review, early-phase and emerging trial data surrounding the use of these promising agents in HER2-positive MBC will be discussed. British Journal of Cancer (2012) 106, 6-13. doi:10.1038/bjc.2011.516 www.bjcancer.com (C) 2012 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available